About Protara Therapeutics, Inc.
https://www.protaratx.comProtara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations.
CEO
Jesse Shefferman
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2020-01-10 | Reverse | 1:40 |
ETFs Holding This Stock
Summary
Showing Top 3 of 47
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
JANUS HENDERSON GROUP PLC
Shares:4.23M
Value:$20.9M
BLACKROCK, INC.
Shares:2.23M
Value:$11.01M
VELAN CAPITAL INVESTMENT MANAGEMENT LP
Shares:2.14M
Value:$10.57M
Summary
Showing Top 3 of 88
About Protara Therapeutics, Inc.
https://www.protaratx.comProtara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $14.67M ▼ | $-13.26M ▲ | 0% | $-0.31 ▲ | $-11.67M ▲ |
| Q2-2025 | $0 | $16.59M ▲ | $-14.96M ▼ | 0% | $-0.35 ▼ | $-16.49M ▼ |
| Q1-2025 | $0 | $14.12M ▼ | $-11.91M ▲ | 0% | $-0.29 ▲ | $-14.04M ▲ |
| Q4-2024 | $0 | $14.31M ▲ | $-12.77M ▼ | 0% | $-0.48 ▲ | $-14.23M ▼ |
| Q3-2024 | $0 | $12.33M | $-11.22M | 0% | $-0.5 | $-12.25M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $132.67M ▲ | $144.64M ▼ | $12.35M ▼ | $132.29M ▼ |
| Q2-2025 | $122.22M ▼ | $156.93M ▼ | $12.51M ▲ | $144.42M ▼ |
| Q1-2025 | $124.36M ▼ | $168.56M ▼ | $10.07M ▼ | $158.48M ▼ |
| Q4-2024 | $170.29M ▲ | $181.45M ▲ | $14.32M ▲ | $167.13M ▲ |
| Q3-2024 | $81.5M | $94.09M | $12.3M | $81.79M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-13.26M ▲ | $-12.45M ▼ | $-6.51M ▲ | $13K ▲ | $-18.95M ▲ | $-12.46M ▼ |
| Q2-2025 | $-14.96M ▼ | $-12.25M ▲ | $-47.72M ▲ | $8K ▼ | $-59.97M ▲ | $-12.27M ▲ |
| Q1-2025 | $-11.91M ▲ | $-14.71M ▼ | $-58.35M ▼ | $1.73M ▼ | $-71.34M ▼ | $-14.76M ▼ |
| Q4-2024 | $-12.77M ▼ | $-9.31M ▼ | $22.5M ▲ | $97.85M ▲ | $111.04M ▲ | $-9.31M ▼ |
| Q3-2024 | $-11.22M | $-8.43M | $-29.39M | $0 | $-37.82M | $-8.44M |
CEO
Jesse Shefferman
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2020-01-10 | Reverse | 1:40 |
ETFs Holding This Stock
Summary
Showing Top 3 of 47
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
JANUS HENDERSON GROUP PLC
Shares:4.23M
Value:$20.9M
BLACKROCK, INC.
Shares:2.23M
Value:$11.01M
VELAN CAPITAL INVESTMENT MANAGEMENT LP
Shares:2.14M
Value:$10.57M
Summary
Showing Top 3 of 88